Literature DB >> 11351112

Alexithymia in DSM-IV disorder: comparative evaluation of somatoform disorder, panic disorder, obsessive-compulsive disorder, and depression.

B Bankier1, M Aigner, M Bach.   

Abstract

The purpose of this study was a direct comparative evaluation of alexithymia in patients with somatoform disorder, panic disorder, obsessive-compulsive disorder, and depression, taking into account the multidimensionality of the alexithymia construct. The authors administered the Structured Clinical Interview for DSM-IV (SCID) and the Toronto Alexithymia Scale (TAS-20) to a sample of 234 subjects. Panic disorder, but no other diagnosis, was significantly related to lower TAS-20 total scores (P=0.000). Regarding TAS-20 subfactors, Factor 1 was significantly associated with somatoform disorder (P=0.006) and depression (P=0.002), Factor 2 was significantly associated with depression (P=0.025), and Factor 3 was significantly associated with obsessive-compulsive disorder (P=0.001), whereas panic disorder showed a significant negative correlation with Factor 3 (P=0.001). The relationships of the three subfactors with various DSM-IV diagnoses and sociodemographic variables emphasize the multidimensionality of alexithymia.

Entities:  

Mesh:

Year:  2001        PMID: 11351112     DOI: 10.1176/appi.psy.42.3.235

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  36 in total

1.  Alexithymia, depression, and cognition in patients with Parkinson's disease.

Authors:  Gulay Kenangil; Mehmet Demir; Esma Tur; Fusun Domac
Journal:  Acta Neurol Belg       Date:  2021-01-16       Impact factor: 2.396

2.  Alexithymia and 7.5-year incidence of compensated low back pain in 1207 urban public transit operators.

Authors:  Wolf E Mehling; Niklas Krause
Journal:  J Psychosom Res       Date:  2007-06       Impact factor: 3.006

3.  Insight and alexithymia in adult outpatients with obsessive-compulsive disorder.

Authors:  Domenico De Berardis; Daniela Campanella; Francesco Gambi; Gianna Sepede; Gabriele Salini; Alessandro Carano; Raffaella La Rovere; Lucia Pelusi; Laura Penna; Alessandra Cicconetti; Carla Cotellessa; Rosa Maria Salerno; Filippo Maria Ferro
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-02-21       Impact factor: 5.270

4.  The predictive value of the Toronto Alexithymia Scale among patients with asthma.

Authors:  Jonathan M Feldman; Paul M Lehrer; Stuart M Hochron
Journal:  J Psychosom Res       Date:  2002-12       Impact factor: 3.006

5.  Brain structural correlates of alexithymia in patients with major depressive disorder

Authors:  Katharina Förster; Verena Enneking; Katharina Dohm; Ronny Redlich; Susanne Meinert; Adina Isabel ` Geisler; Elisabeth Johanna Leehr; Harald Kugel; Bernhard T. Baune; Volker Arolt; Pienie Zwitserlood; Dominik Grotegerd; Udo Dannlowski
Journal:  J Psychiatry Neurosci       Date:  2020-03-01       Impact factor: 6.186

6.  Personality and Alexithymic Disparity in Obsessive-Compulsive Disorder Based on Washing and Checking.

Authors:  Hwa-Sheng Tang; Po-Fei Chen; For-Wey Lung
Journal:  Psychiatr Q       Date:  2018-06

7.  Alexithymia and emotional intelligence in patients with panic disorder, generalized anxiety disorder and major depressive disorder.

Authors:  Elif Onur; Tunc Alkın; Michael J Sheridan; Thomas N Wise
Journal:  Psychiatr Q       Date:  2013-09

8.  Alexithymia and posttraumatic stress disorder following asthma attack.

Authors:  Man Cheung Chung; Natalie Wall
Journal:  Psychiatr Q       Date:  2013-09

9.  The Relationship between Alexithymia and General Symptoms of Patients with Depressive Disorders.

Authors:  Ju Hee Kim; Seung Jae Lee; Hyo Deog Rim; Hea Won Kim; Geum Ye Bae; Sung Man Chang
Journal:  Psychiatry Investig       Date:  2008-09-30       Impact factor: 2.505

10.  Alexithymia and Stress Response Patterns among Patients with Depressive Disorders in Korea.

Authors:  Hea Won Kim; Hyo Deog Rim; Ju Hee Kim; Seung Jae Lee
Journal:  Psychiatry Investig       Date:  2009-03-31       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.